Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Br J Haematol. 2012 Dec 13;160(4):530–537. doi: 10.1111/bjh.12163

Figure 3. Cumulative incidence of venous thromboembolism with higher or lower concentration of tissue factor-bearing microparticles.

Figure 3

The cumulative incidence of venous thromboembolism (VTE) at 2 months in the group of patients with higher levels of tissue factor-bearing microparticles randomized to observation was 27.2% (blue) compared with 5.6% (green) in the group treated with enoxaparin (Gray test P value =0.06). The cumulative incidence of VTE at 2-months for the cohort with lower levels of tissue factor-bearing microparticles was 7.2% (red).